Roche and Causaly Webinar: AI for smarter portfolio management - Moving beyond serendipity in early R&D

Peggy Westlotorn
published on April 12, 2022

Pharmaceutical research is inherently risky and failed or discontinued projects are an inevitable part of the R&D process. A key challenge is that competitive information and the biological validation necessary to decide on target selection and clinical development is often unavailable in a timely or holistic manner. With the volume of information increasing exponentially – from biomedical literature, to labels, to clinical trials, to conference readouts, to news – tackling this problem is a massive challenge.

In this on-demand webinar Ivan John Clement, previous R&D Portfolio Data Strategy Lead from Roche and Yiannis Kiachopoulos, CEO of Causaly discuss how:

  • Roche is partnering with Causaly to build a unified and systematic approach to drive better project and portfolio level decisions.
  • A user-centric application of AI for smarter portfolio management leads to value creation in early R&D.
  • Causaly’s machine-reading algorithms truly understand text like a human does, allowing Roche and other users to receive simple answers to complex questions within seconds.

Request access to the recording here

Causaly announces the appointment of Chris Tunnell as SVP Global Sales

Causaly, a world leader in R&D analytics that allows researchers and specialists to navigate the intricate landscape of research, today...

Causaly announces the appointment of Saikat Das as VP Marketing

Causaly, a leader in R&D Analytics that allows researchers and specialists to intuitively map and navigate the intricate landscape of...

  • News

Alex Meissner joins Causaly as VP Strategy & Business Operations

Causaly, a leader in R&D Analytics that allows researchers and specialists to intuitively map and navigate the intricate landscape of...

  • News

Sign up for Causaly newsletter